Addex Therapeutics Ltd’s Shares Offering

Homburger advised Addex Therapeutics Ltd. on the deal.

Addex Therapeutics Ltd announced the global offering of 6,900,000 shares (New Shares) (including 6,750,000 shares delivered in the form of 1,125,000 American Depositary Shares, or ADSs) on the Nasdaq Capital Market at a price of approximately CHF 1.47 per share or $ 10.00 per ADS, including the full exercise of the underwriter’s option to purchase additional securities. The New Shares have been listed on the SIX Swiss Exchange and the new ADS have been listed on Nasdaq.

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

The Homburger team comprised Frank Gerhard (Picture), Karin Mattle, Guy Deillon, Lorenzo Togni, and Vincent Croisier.

Involved fees earner: Vincent Croisier – Homburger; Guy Deillon – Homburger; Frank Gerhard – Homburger; Karin Mattle – Homburger; Lorenzo Togni – Homburger;

Law Firms: Homburger;

Clients: Addex Therapeutics Ltd;